New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 11, 2014
14:50 EDTBSXBoston Scientific's LATITUDE demonstrated reduction in mortality/hospitalization
Patients using the Boston Scientific Corporation LATITUDE Remote Patient Management system with wireless telemetry demonstrated significantly lower mortality and fewer hospitalizations than patients with LATITUDE-compatible devices who were not followed on the system, according to results from the PREDICt-RM study. The results were presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco. PREDICt-RM demonstrated a 33% relative reduction in the risk of death in patients with Boston Scientific ICDs and CRT-Ds who were remotely monitored via the LATITUDE wireless remote monitoring system, compared to Boston Scientific ICD and CRT-D patients who were not remotely monitored. Additionally, these patients experienced a 19% relative reduction in hospitalizations for any cause. The study outcomes were presented by Dr. Joseph Akar, associate professor of medicine at Yale University and the Center for Outcomes Research and Evaluation, CORE, in New Haven, CT, and are a result of a research collaboration between Yale CORE, the American College of Cardiology, ACC, and Boston Scientific. "The PREDICt-RM results demonstrate improved outcomes for those ICD and CRT-D patients using the LATITUDE wireless Remote Patient Management system," said Dr. Joseph Akar. "Despite the widespread availability of this technology, we know that it is underutilized. Our hope is that this study may inform clinical practice guidelines and promote the routine use of this technology in daily practice."
News For BSX From The Last 14 Days
Check below for free stories on BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
10:56 EDTBSXStocks with call strike movement; NRG BSX
NRG Energy (NRG) January 35 call option implied volatility decreased 2% to 24, NRG Energy Boston Scientific (BSX) January 15 call option implied volatility decreased 2% to 25 according to IVolatility.
08:28 EDTBSXBoston Scientific sees FY operating margin approaching 20%
Subscribe for More Information
07:04 EDTBSXBoston Scientific raises FY14 adjusted EPS to 79c-83c from 77c-82c
Subscribe for More Information
07:02 EDTBSXBoston Scientific sees Q3 adjusted EPS 18c-20c, consensus 19c
Subscribe for More Information
07:02 EDTBSXBoston Scientific reports Q2 Rhythm Management revenue growth of 7%
Subscribe for More Information
07:01 EDTBSXBoston Scientific reports Q2 adjusted EPS 21c, consensus 19c
Reports Q2 revenue $1.87B, consensus $1.87B
July 23, 2014
17:10 EDTBSXBoston Scientific receives CE Mark for Agent Drug Coated Balloon
Subscribe for More Information
15:30 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
July 22, 2014
08:25 EDTBSXBoston Scientific risk/reward favorable into Q2 results, says RBC Capital
Subscribe for More Information
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Subscribe for More Information
July 14, 2014
19:19 EDTBSXBoston Scientific receives CE Mark for 25 mm Lotus Valve System
Subscribe for More Information
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use